Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute coronary syndrome, especially if the patient has received coronary angioplasty. Few data are available in the real world in terms of safety and efficacy of prasugrel versus clopidogrel in this clinical context. This registry involved 12227 patients undergoing<a href="https://solaci.org/en/2015/06/24/translate-acs-one-year-prasugrel-versus-clopidogrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

The aim of this study was to compare angioplasty guided by fractional flow reserve (FFR) versus conventional angiography in bifurcations treated with provisional stent technique for lateral branch. The study included patients with bifurcations 1,1,1 or 0,1,1 of Medina classification and lateral branches, superior to 2.5 mm. 2nd generation pharmacological stents were used.&nbsp; After stent<a href="https://solaci.org/en/2015/06/24/dkcrush-vi-ffr-versus-conventional-angiography-in-true-bifurcations-and-provisional-stent/" title="Read more" >...</a>

TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral branch fund the coronary tree. Between 2008 and 2011 this work included 52 patients with left main coronary unprotected lesions who underwent angioplasty with drug-eluting stent in the coronary trunk left<a href="https://solaci.org/en/2015/06/24/tryton-dedicated-bifurcation-stent-in-left-main-coronary-artery/" title="Read more" >...</a>

The use of FFR to guide treatment showed improved outcomes in previous studies. However, there are few data on the routine use of the method and its impact on modifying therapeutic decisions for injury and by patient. The aim of this study was to evaluate the routine use of FFR in the real world. All<a href="https://solaci.org/en/2015/06/24/post-it-the-ffr-modifies-strategy-in-almost-half-of-patients/" title="Read more" >...</a>

The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified in the discontinuation of dual antiplatelet therapy: 1) discontinuation for medical guidance, 2) transient discontinuation for less than 15 days for surgery and 3) permanent abandonment of it by non-adherence or<a href="https://solaci.org/en/2015/06/24/paris-register-non-adherence-impact-to-antiplatelet-therapy-among-men-and-women/" title="Read more" >...</a>

The individual variability to platelet response of clopidogrel is related to several mechanisms with high intrinsic platelet reactivity, variability in drug metabolism, drug interactions, etc. The hepatic cytochrome P450 system plays a key role in the metabolism of clopidogrel, and the CYP2C19 allele loss of function is associated with high platelet reactivity with clopidogrel use<a href="https://solaci.org/en/2015/06/24/triplete-reset-trial-comparison-of-platelet-reactivity-with-clopidogrel-prasugrel-or-ticagrelor/" title="Read more" >...</a>

P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This study evaluated the administration of prasugrel at the time of diagnosis of ACS or after performing coronary angiography when angioplasty was already decided. 4033 patients were included experiencing an NSTE-ACS troponin positive who had planned angiography between 2<a href="https://solaci.org/en/2015/06/24/accoast-pretreatment-with-prasugrel-in-non-st-elevation-acute-coronary-syndrome-nste-acs-offers-no-benefit-and-increased-bleeding/" title="Read more" >...</a>

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the number of peripheral angioplasties has increased, proving highly effective for this condition. The aim of this study was to compare the clinical effectiveness of endovascular revascularization plus exercise versus exercise alone in patients with intermittent claudication. The study<a href="https://solaci.org/en/2015/06/24/erase-endovascular-treatment-plus-exercise-versus-exercise-alone-to-treat-claudication/" title="Read more" >...</a>

The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) and another with degradable polymer (Excel, JW Medical System Ltd, Weihai, China). A randomized (2:1) was used, open and non-inferiority, including 1923 patients in 30 centers in China (December 2008<a href="https://solaci.org/en/2015/06/24/evolution-comparative-study-of-non-inferiority-of-two-sirolimus-eluting-stents-one-with-permanent-polymer-and-the-other-with-degradable-polymer/" title="Read more" >...</a>

This randomized trial with an initial plan to include 1832 patients, compared stent implantation guided by fractional flow reserve (FFR) versus optimal medical treatment. In this study, we invasively evaluated the severity of lesion by FFR. Of this population, only patients who had lesions with significant translesional gradient (FFR &lt;0.9) were included in the study<a href="https://solaci.org/en/2015/06/24/fame-ii-this-randomized-trial-compared-a-stent-implantation-guided-by-fractional-flow-reserve-ffr-with-optimal-medical-treatment/" title="Read more" >...</a>